恒瑞医药子公司复方营养注射液获批上市累计研发投入约8390万元

财中社05-19 17:12

　　5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。

　　该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。

　　该药品采用三腔袋包装，便于临床使用，且研究表明其成本更低，无菌性更有保障。原研药品由德国贝朗医疗股份有限公司开发，并在多个欧洲国家获批上市。

　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2636563834?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-19 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636563834","market":"sh","top_or_hot":-1,"title":"恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元","media":"财中社","content":"<html><body><div>\n<p>　　5月19日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。</p><p>　　该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。</p><p>　　该药品采用三腔袋包装，便于临床使用，且研究表明其成本更低，无菌性更有保障。原研药品由德国贝朗医疗股份有限公司开发，并在多个欧洲国家获批上市。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　5月19日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。</p><p>　　该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。</p><p>　　该药品采用三腔袋包装，便于临床使用，且研究表明其成本更低，无菌性更有保障。原研药品由德国贝朗医疗股份有限公司开发，并在多个欧洲国家获批上市。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202605193742055768.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605193742055768.html","article_id":"2636563834","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636563834","pubTimestamp":1779181920,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK1191":"制药","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","IPOS":"Renaissance International IPO ETF","BK0060":"抗癌","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0028":"国家队","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0196":"行业龙头","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0239":"医药制造","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK0183":"MSCI概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","01276":"恒瑞医药","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H"},"translate_title":"Compound Nutrition Injection, a subsidiary of Hengrui Pharmaceutical, was approved for listing with a cumulative R&D investment of approximately 83.9 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5,"IPOS":1.5},"content_text":"5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。　　该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。　　该药品采用三腔袋包装，便于临床使用，且研究表明其成本更低，无菌性更有保障。原研药品由德国贝朗医疗股份有限公司开发，并在多个欧洲国家获批上市。　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636563834","isCrawlerRequest":true}

恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元

精彩评论

恒瑞医药子公司复方营养注射液获批上市累计研发投入约8390万元